ketanserin has been researched along with Conus Medullaris Syndrome in 2 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Siegal, T | 2 |
| Hughes, EW | 1 |
| Hodkinson, BP | 1 |
2 other studies available for ketanserin and Conus Medullaris Syndrome
| Article | Year |
|---|---|
Serotonergic manipulations in experimental neoplastic spinal cord compression.
Topics: Animals; Capillary Permeability; Cyproheptadine; Dexamethasone; Dinoprostone; Dose-Response Relation | 1993 |
Carcinoid syndrome: the combined use of ketanserin and octreotide in the management of an acute crisis during anaesthesia.
Topics: Anesthesia; Breast Neoplasms; Carcinoid Tumor; Female; Humans; Hypertension; Intraoperative Complica | 1989 |